Nordea Investment Management AB Buys 5,012 Shares of Masimo Co. (MASI)
Nordea Investment Management AB grew its stake in Masimo Co. (NASDAQ:MASI) by 25.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,816 shares of the medical equipment provider’s stock after purchasing an additional 5,012 shares during the quarter. Nordea Investment Management AB’s holdings in Masimo were worth $2,148,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Fortaleza Asset Management Inc. bought a new stake in Masimo during the second quarter worth $106,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Masimo by 13.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock worth $184,000 after acquiring an additional 236 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in Masimo by 78.3% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock worth $182,000 after acquiring an additional 925 shares during the period. Advisor Group Inc. lifted its holdings in Masimo by 38.4% during the second quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock worth $216,000 after acquiring an additional 655 shares during the period. Finally, Daiwa Securities Group Inc. bought a new stake in Masimo during the second quarter worth $219,000. Institutional investors own 83.74% of the company’s stock.
MASI has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Thursday, November 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $108.00 price target on shares of Masimo in a report on Friday, November 3rd. BTIG Research upgraded Masimo from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Monday, August 14th. Finally, BidaskClub lowered Masimo from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $97.17.
In other news, EVP Yongsam Lee sold 5,900 shares of Masimo stock in a transaction on Friday, December 1st. The stock was sold at an average price of $88.31, for a total value of $521,029.00. Following the completion of the transaction, the executive vice president now directly owns 70,800 shares in the company, valued at $6,252,348. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the transaction, the director now owns 73,249 shares of the company’s stock, valued at $6,592,410. The disclosure for this sale can be found here. Insiders sold 53,074 shares of company stock valued at $4,737,245 over the last three months. Company insiders own 16.60% of the company’s stock.
Shares of Masimo Co. (MASI) opened at $87.11 on Thursday. Masimo Co. has a 52-week low of $62.17 and a 52-week high of $104.71. The stock has a market capitalization of $4,552.74, a price-to-earnings ratio of 33.76, a price-to-earnings-growth ratio of 2.97 and a beta of 0.72.
Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.17. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The business had revenue of $193.69 million during the quarter, compared to the consensus estimate of $189.01 million. During the same period last year, the business posted $0.52 earnings per share. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. analysts anticipate that Masimo Co. will post 2.95 EPS for the current fiscal year.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.